Peiyi Zhang

Also affiliated with Henan University of Technology, Zhengzhou University, Henan University of Engineering, Medicina, Institute of Forest Ecology, Environment and Protection, Nanjing Product Quality Supervision and Inspection Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells”.

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

Haematologica(2023)10.3324/haematol.2022.281915

N/A

1.6DataRank · unranked

71 citations

Lina Han, Cassandra L. Ramage, Zhe Wang, Connie C. Weng, Lei Yang +15 more

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Nature Communications(2020)10.1038/s41467-020-15838-0

N/A

0.838DataRank · unranked

266 citations

Xuan Zhang, Jianhui Chang, Ha‐Neui Kim, Peiyi Zhang, Yingying Wang +17 more

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Journal of Hematology & Oncology(2020)10.1186/s13045-020-00928-9

N/A

0.739DataRank · unranked

137 citations

Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan +11 more

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01241-3

N/A

0.621DataRank · unranked

62 citations

J Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta +9 more

A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice

Nature Aging(2025)10.1038/s43587-025-00811-7

N/A

0.593DataRank · unranked

51 citations

Natacha Jn-Simon, Yonghan He, Chunbao Sun, Peiyi Zhang, Wanyi Hu +11 more

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

Nature Communications(2024)10.1038/s41467-024-46922-4

N/A

0.590DataRank · unranked

50 citations

Dongwen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak +8 more

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR

Neoplasia(2024)10.1016/j.neo.2024.101070

N/A

0.330DataRank · unranked

8 citations

Gerik W. Tushoski-Alemán, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Zhiguang Huo +6 more

PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.27.582353

N/A

0.312DataRank · unranked

7 citations

Lin Cao, J Wiegand, Peiyi Zhang, Maria Zajac‐Kaye, Frederic J. Kaye +3 more

Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E

ACS Omega(2021)10.1021/acsomega.0c05658

N/A

0DataRank · unranked

4 citations

Pratik Pal, Peiyi Zhang, Xuan Zhang, Guangrong Zheng, Matthew Burke

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

JCI Insight(2022)10.1172/jci.insight.161820

N/A

0DataRank · unranked

27 citations

Denise Ng, Gadi Lalazar, Carly Rosemore, Tova M. Finkelstein, Rachael D. Migler +13 more

Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in mice

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.09.12.507616

N/A

0DataRank · unranked

0 citations

Patrick Kellish, Nick Connis, Dinesh Thummuri, J Wiegand, Peiyi Zhang +14 more

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

Cell Death Discovery(2023)10.1038/s41420-022-01296-8

N/A

0DataRank · unranked

43 citations

Patrick Kellish, Nick Connis, Dinesh Thummuri, J Wiegand, Peiyi Zhang +14 more

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

Cells(2024)10.3390/cells13060528

N/A

0DataRank · unranked

29 citations

Lin Cao, J Wiegand, Peiyi Zhang, Maria Zajac‐Kaye, Frederic J. Kaye +3 more

Discovery of XZ338, a highly potent BCL-XL degrader

European Journal of Medicinal Chemistry(2025)10.1016/j.ejmech.2025.117624

N/A

0DataRank · unranked

5 citations

Dinesh Thummuri, Wanyi Hu, Xingui Liu, Peiyi Zhang, Shuo Zhou +3 more

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

RSC Medicinal Chemistry(2025)10.1039/d5md00119f

N/A

0DataRank · unranked

3 citations

Dinesh Thummuri, Wanyi Hu, Sajid Khan, Yonghan He, Xuan Zhang +5 more

Unveiling BCL-xL-specific PROTAC Efficiency and Dissociation Mechanisms Using Native Mass Spectrometry

ChemRxiv(2025)10.26434/chemrxiv-2025-zfjsj

N/A

0DataRank · unranked

1 citations

Kailyn L. Nonhof, Digant Nayak, Peiyi Zhang, Olivia E. Dioli, Guangrong Zheng +4 more

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112186

N/A

0DataRank · unranked

115 citations

Dinesh Thummuri, Xingui Liu, Wanyi Hu, Peiyi Zhang, Sajid Khan +4 more

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112397

N/A

0DataRank · unranked

65 citations

Yonghan He, Peiyi Zhang, Vivekananda Budamagunta, Dongwen Lv, Dinesh Thummuri +6 more

Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production

Bioorganic & Medicinal Chemistry(2020)10.1016/j.bmc.2020.115498

N/A

0DataRank · unranked

8 citations

Zhengya Gao, Qiang Fu, Lin Song, Peiyi Zhang, Xuan Zhang +5 more

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Exploration of Targeted Anti-tumor Therapy(2020)10.37349/etat.2020.00017

N/A

0DataRank · unranked

23 citations

Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng +1 more

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Nature Communications(2021)10.1038/s41467-021-27210-x

N/A

0DataRank · unranked

149 citations

Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang +19 more

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0474

N/A

0DataRank · unranked

74 citations

Sajid Khan, Patrick W. Underwood, Peiyi Zhang, J Wiegand, Xuan Zhang +13 more

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

Nature Communications(2021)10.1038/s41467-021-21573-x

N/A

0DataRank · unranked

55 citations

Umasankar De, Sajid Khan, Yuewan Luo, Myung‐Chul Kim, Haijun Yu +14 more